Development and Validation of the Patient/Caregiver Reported Hydroxyurea Evaluation of Adherence for Life (HEAL) Scale

References

• Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018–2031. doi:10.1016/S0140-6736(10)61029-X
   PubMed Web of Science ®Google Scholar
• Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512–S521. doi:10.1016/j.amepre.2009.12.022
   PubMed Web of Science ®Google Scholar
• Meier ER, Rampersad A. Pediatric sickle cell disease: past successes and future challenges. Pediatr Res. 2017;81(1–2):249–258. doi:10.1038/pr.2016.204
   PubMed Web of Science ®Google Scholar
• Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol. 2006;38(8):1237–1243. doi:10.1016/j.biocel.2006.01.010
   PubMed Web of Science ®Google Scholar
• Piccin A, Murphy C, Eakins E, et al. Circulating microparticles, protein C, free protein S and endothelial vascular markers in children with sickle cell anaemia. J Extracell Vesicles. 2015;4:28414. doi:10.3402/jev.v4.28414
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 2013;128(2):110–116. doi:10.1177/003335491312800206
   PubMed Web of Science ®Google Scholar
• Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447–3452. doi:10.1182/blood-2009-07-233700
   PubMed Web of Science ®Google Scholar
• Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol. 1992;19(3 Suppl 9):1–10.
   PubMed Web of Science ®Google Scholar
• From the Centers for Disease Control and Prevention. Mortality among children with sickle cell disease identified by newborn screening during 1990–1994--California, Illinois, and New York. JAMA. 1998;279(14):1059–1060. doi:10.1001/jama.279.14.1059
   PubMed Web of Science ®Google Scholar
• Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988;318(2):96–99. doi:10.1056/NEJM198801143180207
   PubMed Web of Science ®Google Scholar
• Orringer EP, Blythe DS, Johnson AE, Phillips G, Dover GJ, Parker JC. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood. 1991;78(1):212–216. doi:10.1182/blood.V78.1.212.212
   PubMed Web of Science ®Google Scholar
• Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol. 1997;34(3 Suppl 3):15–21.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322. doi:10.1056/NEJM199505183322001
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672. doi:10.1016/S0140-6736(11)60355-3
   PubMed Web of Science ®Google Scholar
• Nottage KA, Hankins JS, Smeltzer M, et al. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. PLoS One. 2013;8(8):e72077. doi:10.1371/journal.pone.0072077
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012;120(22):4304–10;quiz 4448. doi:10.1182/blood-2012-03-419879
   PubMed Web of Science ®Google Scholar
• Wang WC, Zou P, Hwang SN, et al. Effects of hydroxyurea on brain function in children with sickle cell anemia. Pediatr Blood Cancer. 2021;68(10):e29254. doi:10.1002/pbc.29254
   PubMed Web of Science ®Google Scholar
• Fields ME, Guilliams KP, Ragan D, et al. Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemia. Blood. 2019;133(22):2436–2444. doi:10.1182/blood-2018-09-876318
   PubMed Web of Science ®Google Scholar
• Lanzkron S, Haywood C, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol. 2006;81(12):927–932. doi:10.1002/ajh.20703
   PubMed Web of Science ®Google Scholar
• Haywood C, Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011;86(1):85–87. doi:10.1002/ajh.21883
   PubMed Web of Science ®Google Scholar
• Oyeku SO, Driscoll MC, Cohen HW, et al. Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease. Pediatr Blood Cancer. 2013;60(4):653–658. doi:10.1002/pbc.24381
   PubMed Web of Science ®Google Scholar
• Patel NG, Lindsey T, Strunk RC, DeBaun MR. Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis. Pediatr Blood Cancer. 2010;55(3):554–556. doi:10.1002/pbc.22605
   PubMed Web of Science ®Google Scholar
• Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R. Hydroxyurea adherence and associated outcomes among medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86(3):273–277. doi:10.1002/ajh.21968
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156(3):415–419. doi:10.1016/j.jpeds.2009.09.044
   PubMed Web of Science ®Google Scholar
• Creary S, Chisolm D, Stanek J, Hankins J, O’Brien SH. A multidimensional electronic hydroxyurea adherence intervention for children with sickle cell disease: single-arm before-after study. JMIR Mhealth Uhealth. 2019;7(8):e13452. doi:10.2196/13452
   PubMed Web of Science ®Google Scholar
• Brandow AM, Jirovec DL, Panepinto JA. Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization. Am J Hematol. 2010;85(8):611–613. doi:10.1002/ajh.21749
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer. 2012;59(2):365–371. doi:10.1002/pbc.24178
   PubMed Web of Science ®Google Scholar
• Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362–1369. doi:10.1056/NEJMct0708272
   PubMed Web of Science ®Google Scholar
• Brandow AM, Panepinto JA. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol. 2011;86(9):804–806. doi:10.1002/ajh.22101
   PubMed Web of Science ®Google Scholar
• Drotar D. Treatment adherence in patients with sickle cell anemia. J Pediatr. 2010;156(3):350–351. doi:10.1016/j.jpeds.2009.10.035
   PubMed Web of Science ®Google Scholar
• Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi:10.1155/2015/217047
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol. 1998;20(1):26–31. doi:10.1097/00043426-199801000-00004
   PubMed Web of Science ®Google Scholar
• Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter study of hydroxyurea. Blood. 1997;89(3):1078–1088. doi:10.1182/blood.V89.3.1078
   PubMed Web of Science ®Google Scholar
• Ender KL, Lee MT, Sheth S, et al. Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyurea. J Pediatr Hematol Oncol. 2011;33(7):496–499. doi:10.1097/MPH.0b013e31822dcc21
   PubMed Web of Science ®Google Scholar
• Duncan N, Kronenberger W, Roberson C, Shapiro A. VERITAS-pro: a new measure of adherence to prophylactic regimens in haemophilia. Haemophilia. 2010;16(2):247–255. doi:10.1111/j.1365-2516.2009.02129.x
   PubMed Web of Science ®Google Scholar
• Duncan NA, Kronenberger WG, Roberson CP, Shapiro AD. VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia. 2010;16(1):47–53. doi:10.1111/j.1365-2516.2009.02094.x
   PubMed Web of Science ®Google Scholar
• Duncan NA, Kronenberger WG, Hampton KC, et al. A validated measure of adherence to antibiotic prophylaxis in children with sickle cell disease. Patient Prefer Adherence. 2016;10:983–992. doi:10.2147/PPA.S103874
   PubMed Web of Science ®Google Scholar
• Duncan NA, Kronenberger WG, Roberson CP, Janson IA, Shapiro AD. Adherence is a human behaviour, assessing it requires multimethod evaluation with validated measures: comment on Guedes VG et al (2019). Haemophilia. 2020;26(6):934–936. doi:10.1111/hae.14022
   PubMed Web of Science ®Google Scholar
• Estepp JH, Winter B, Johnson M, Smeltzer MP, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. Pediatr Blood Cancer. 2014;61(11):2031–2036. doi:10.1002/pbc.25177
   PubMed Web of Science ®Google Scholar
• Okocha EC, Gyamfi J, Ryan N, et al. Barriers to therapeutic use of hydroxyurea for sickle cell disease in Nigeria: a cross-sectional survey. Front Genet. 2021;12:765958. doi:10.3389/fgene.2021.765958
   PubMed Web of Science ®Google Scholar
• Fogarty H, Gaul A, Syed S, et al. Adherence to hydroxyurea, health-related quality of life domains and attitudes towards a smartphone app among Irish adolescents and young adults with sickle cell disease. Ir J Med Sci. 2022;191(2):809–816. doi:10.1007/s11845-021-02588-1
   PubMed Web of Science ®Google Scholar